Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 764 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Bio-specimen samples Clear all
Recruiting Phase 1 Interventional

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

NCT05805371
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes, Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, External Beam Radiation Therapy, Leukapheresis, Lymphodepletion Therapy
Biological · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 9:16 AM EDT
Recruiting No phase listed Observational

Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens

NCT04968834
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myeloproliferative Syndrome
Interventions
Genomic profiling
Genetic
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 30 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
8
States / cities
Hartford, Connecticut • Portland, Maine • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 23, 2026, 9:16 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

CONNECTing to LungCare

NCT06213532
View directory record Official record
Conditions
Smoking Cessation, Cigarette Smoking-Related Carcinoma, Lung Carcinoma
Interventions
Smoking Cessation Intervention, Saliva Collection, Survey Administration
Behavioral · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Diagnostic HIV Ag/Ab Combo Assay

NCT00933933
View directory record Official record
Conditions
Human Immunodeficiency Viruses
Interventions
ARCHITECT HIV Ag/Ab Combo
Device
Lead sponsor
Abbott Diagnostics Division
Industry
Eligibility
Not listed
Enrollment
635 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
13
States / cities
Phoenix, Arizona • St. Petersburg, Florida • Springfield, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Oct 23, 2026, 9:16 AM EDT
Recruiting Phase 2 Interventional

Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors

NCT06113016
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Breast Carcinoma
Interventions
Biospecimen Collection, Educational Intervention, Exercise Intervention, Fisetin, Physical Performance Testing, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
6
States / cities
Alhambra, California • Beverly Hills, California • Burbank, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 23, 2026, 9:16 AM EDT
Completed Phase 2 Interventional Results available

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

NCT05730712
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Echocardiography, Enzalutamide, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 23, 2026, 9:16 AM EDT
Active, not recruiting Phase 1 Interventional

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02595931
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Carcinoma, Refractory Colorectal Carcinoma, Refractory Lung Small Cell Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Pancreatic Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Pancreatic Carcinoma
Interventions
Berzosertib, Biopsy Specimen, Biospecimen Collection, Computed Tomography, Irinotecan Hydrochloride
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
23
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 9:16 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Developing Non-Communicable Disease Registries in Africa : A Step Towards Providing Quality Data for Improving Patient Outcomes

NCT03473795
View directory record Official record
Conditions
Non-Communicable Disease
Interventions
Questionnaire forms, Bio-specimen samples
Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6,990 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 23, 2026, 9:16 AM EDT
Terminated Phase 4 Interventional

Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

NCT05183828
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma of No Special Type
Interventions
Biospecimen Collection, Letrozole, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 23, 2026, 9:16 AM EDT
Completed No phase listed Observational

Immuno-regulatory Profiling of T Cells in GVHD Treated With Extracorporeal Photopheresis

NCT03851601
View directory record Official record
Conditions
GVHD
Interventions
blood samples
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 23, 2026, 9:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

N600X Low Saturation Accuracy Validation

NCT05532670
View directory record Official record
Conditions
Hypoxia
Interventions
Non-Invasive Controlled Hypoxia
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Louisville, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 23, 2026, 9:16 AM EDT
Recruiting Phase 4 Interventional

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

NCT05919329
View directory record Official record
Conditions
Castration Resistant Prostate Cancer, Castration Sensitive Prostate Cancer, Prostate Adenocarcinoma
Interventions
Piflufolastat, PSMA PET/CT Scan, PSMA PET/MRI scan, Biospecimen Collection, Electronic Health Record Review
Drug · Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 9:16 AM EDT
Completed No phase listed Observational

Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer

NCT02370277
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Questionnaire Administration
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 23, 2026, 9:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk of Development of Wheeze and Asthma From 0 to 6 Years of Age

NCT01995175
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Nasal swab sampling, Blood sampling, Diary cards
Procedure · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Up to 6 Years
Enrollment
2,409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
9
States / cities
Oakland, California • Sacramento, California • Santa Clara, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 23, 2026, 9:16 AM EDT
Active, not recruiting Phase 1 Interventional

Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery

NCT00977457
View directory record Official record
Conditions
Prostate Cancer
Interventions
DNA analysis, DNA methylation analysis, RNA analysis, gene expression analysis, polymerase chain reaction, diagnostic laboratory biomarker analysis, therapeutic conventional surgery
Genetic · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
1,045 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 23, 2026, 9:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

SpO2 Accuracy Low Saturation Validation of the OxySoftN Sensor

NCT04811963
View directory record Official record
Conditions
Hypoxia, Desaturation of Blood
Interventions
Non-Invasive Controlled Hypoxia
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Louisville, Colorado
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 23, 2026, 9:16 AM EDT
Recruiting Phase 2 Interventional

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

NCT05564377
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
Interventions
Alpelisib, Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Fulvestrant, Ipatasertib, Leucovorin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Mutation Carrier Screening, Neratinib Maleate, Nilotinib Hydrochloride Monohydrate, Olaparib, Oxaliplatin, Paclitaxel, Palbociclib, Panitumumab, Positron Emission Tomography, Selumetinib Sulfate, Sotorasib
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
2,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
479
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 355 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 23, 2026, 9:16 AM EDT
Recruiting Phase 2 Interventional

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

NCT05554393
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Multigated Acquisition Scan, Venetoclax
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 59 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
175
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 143 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 9:16 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients

NCT03036930
View directory record Official record
Conditions
Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma
Interventions
Biospecimen Collection, HPV Self-Collection, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 49 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 9:16 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating the Impact of a Virtually Supervised Exercise Intervention and Group Counseling on Inflammation and the Microbiome of Smokers at High Risk for Lung Cancer, BE FIT Trial

NCT06445192
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Best Practice, Biospecimen Collection, Exercise Counseling, Exercise Intervention, Medical Device Usage and Evaluation, Physical Performance Testing, Questionnaire Administration, Telemedicine
Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
40 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 23, 2026, 9:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma

NCT00715793
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Decitabine, Temozolomide, biopsy
Drug · Procedure
Lead sponsor
Hussein Tawbi
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Oct 23, 2026, 9:16 AM EDT
Suspended Phase 1 Interventional

AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease

NCT05791448
View directory record Official record
Conditions
Advanced Cholangiocarcinoma, Advanced Hepatocellular Carcinoma, Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver, Refractory Malignant Solid Neoplasm, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, RNA Transcription Modulator AU-409
Procedure · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 23, 2026, 9:16 AM EDT
Withdrawn Not applicable Interventional

Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer

NCT07136493
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, HER2-Positive Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Electronic Health Record Review, Survey Administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
5
States / cities
Goodyear, Arizona • Duarte, California • Irvine, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 23, 2026, 9:16 AM EDT
Not yet recruiting Phase 2 Interventional

Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate Cancer

NCT07860554
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Lutetium Lu 177 Vipivotide Tetraxetan, PSMA PET Scan, Questionnaire Administration, Single Photon Emission Computed Tomography
Procedure · Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 9:16 AM EDT